Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced...

Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM ( Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA )

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL

Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL ( Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany )

Analysis of pre-treatment biomarkers associated with toxicity and durable...

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene...

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy

Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy ( Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA )

Teclistamab-based induction regimens demonstrate manageable safety and efficacy...

Prof Marc Raab - Heidelberg Myeloma Center, Heidelberg, Germany

Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM ( Prof Marc Raab - Heidelberg Myeloma Center, Heidelberg, Germany )

Addition of tafasitamab to lenalidomide plus rituximab significantly improves...

Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma ( Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA )

Pembrolizumab shows improvement in overall survival for clear cell renal cell...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar...

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona...

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Blinatumomab added to chemotherapy improves disease-free survival in newly...

Dr Rachel Rau - University of Washington, Seattle, USA

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL ( Dr Rachel Rau - University of Washington, Seattle, USA )

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML...

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )

More from ecancer